Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP

- Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticated financial institutions, family offices, and leading multinational corporations (strategic investors). PVP III LP's strategic investors include a who's who of market leaders around the world in their respective industries, including Pfizer Inc. (NYSE: PFE), Corning Incorporated (NYSE:GLW), W. L. Gore & Associates, Showa Denko K. K. (TYO:4004), Nissan Chemical Corporation (TYO:4021), Nagase & Co., Ltd. (TYO:8012), and LG Technology Ventures, which is the investment vehicle of LG Chem, Ltd. (KRX: 051910).

As the leading venture capital firm focused on Advanced Materials and Device investing, PVP has an established track record of strong returns and is known by entrepreneurs and corporations globally. PVP also has a reputation for forging deep partnerships with its strategic investors working closely with them on open innovation to identify attractive market opportunities. Building off the success of its first two funds, PVP III LP will continue to focus on investing in start-ups developing breakthrough Advanced Materials and Device innovations while expanding its presence globally.

Dr. John T. Chen , Managing General Partner of PVP, commented, "We are pleased by the strong interest in PVP III LP from new investors and continued support from our existing LPs and are happy to have closed the new fund despite the current global challenges."

Dr. Zachariah Jonasson , Managing General Partner of PVP added, "We are excited to be working with both the most innovative multinational corporations and entrepreneurs globally."

About Phoenix Venture Partners LLC

Phoenix Venture Partners LLC is a leading venture capital firm that invests in and partners with outstanding entrepreneurs to commercialize breakthrough Advanced Materials and Device innovations. PVP's team has an unparalleled track record of founding, building and investing in successful Advanced Materials start-ups across multiple industries. The firm's investment strategy is flexible and predicated on assisting entrepreneurs with customer and supply chain partnerships, business development, as well as with strategic and operational support. PVP collaborates with a select ecosystem of forward-looking global corporations on business development and open innovation interests. PVP is based in the Silicon Valley with a satellite office in Seattle , WA.  For additional information please visit our website at www.phoenix-vp.com or email us at information@phoenix-vp.com .

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/phoenix-venture-partners-llc-raises-3rd-fund-pvp-iii-lp-301214652.html

SOURCE Phoenix Venture Partners, LLC.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...
Data Safety Monitoring Board  Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...

Interactive Chart

Latest Press Releases

Related News